Bavarian Nordic Comes Up On The Rails In RSV Race
Phase III Readout In Mid-2023
GSK and Pfizer are both likely to get FDA approval for their respiratory syncytial virus products shortly but Bavarian Nordic is progressing well with its differentiated five RSV-specific antigen jab.
You may also be interested in...
The second quarter has already seen the approval of Gamida Cell’s cell therapy Omisirge, and with the help of Biomedtracker, Scrip highlights 10 of the more interesting new drug approvals due in the next three months.
The company had its fourth vaccines day, where it talked about its strategy over the next few years for vaccines against COVID-19, RSV, flu and combinations thereof.
The pharma, which has been de-emphasizing vaccines and infectious disease of late, will end its Phase III trial for an RSV vaccine with May approvals pending for both Pfizer’s and GSK’s candidates.